First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 90
NovoEight® volumes continue to grow despite increasing
penetration of long-acting FVIII products
Novo Eight® roll-out continues and the number
of patients has steadily increased
Estimated number
of patients¹
2,000
1,500
1,000
500
Number of launch countries
Number of patients
2014
2015
2016
2017²
Novo Eight® has potential to increase volume
share in select segments and markets
Competitive positioning for NovoEight®
•
•
•
Temperature stabilty at high room temperature and best-in-
class portability
Uptake driven by Novo Nordisk's strong customer focus and
company recognition within the haemophilia community
Continued volume growth especially in less mature markets
with tender opportunities, despite increasing penetration of
long-acting FVIII products
Next generation
Global roll-out of NovoEight® and N8-GP to pave the way for
subcutaneous N8-GP
1 Novo Nordisk estimated accumulated patient number
2 Novo Nordisk estimated accumulated patient number as of October 2017
FVIII: Coagulation factor VIII
novo nordiskView entire presentation